Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer

2006 ◽  
Vol 92 (5) ◽  
pp. 384-388 ◽  
Author(s):  
Mario Scartozzi ◽  
Alfredo Falcone ◽  
Francesca Pucci ◽  
Chiara Braconi ◽  
Chiara Pierantoni ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Effective Treatment ◽  
Mitomycin C ◽  
Treatment Option ◽  
Advanced Colorectal Cancer ◽  
Effective Treatment Option ◽  
Third Line ◽  
Line Chemotherapy

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

2005 ◽  
Vol 56 (1) ◽  
pp. 10-14 ◽  
Author(s):  
Do Hyoung Lim ◽  
Young Suk Park ◽  
Byeong-Bae Park ◽  
Sang Hoon Ji ◽  
Jeeyun Lee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Third Line ◽  
Line Chemotherapy

scholarly journals A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer

2011 ◽  
Vol 2 (6) ◽  
pp. 1253-1256 ◽  
Author(s):  
JUNG HAN KIM ◽  
HYEONG SU KIM ◽  
DAE RO CHOI ◽  
GEUNDOO JANG ◽  
JUNG HYE KWON ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase Ii ◽  
Advanced Colorectal Cancer ◽  
Phase Ii Study ◽  
Third Line ◽  
Line Chemotherapy

scholarly journals A phase 1B study of pegylated liposomal mitomycin-C prodrug with or without capecitabine and bevacizumab in third line chemotherapy of colorectal cancer

2016 ◽  
Vol 27 ◽  
pp. vi202 ◽  
Author(s):  
A.A. Gabizon ◽  
T. Grenader ◽  
E. Tahover ◽  
H. Shmeeda ◽  
T. Golan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitomycin C ◽  
Phase 1B ◽  
Third Line ◽  
Line Chemotherapy

scholarly journals COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease

2020 ◽  
Vol 4 (18) ◽  
pp. 4278-4281 ◽  
Author(s):  
Zahidee Rodriguez ◽  
Andi L. Shane ◽  
Hans Verkerke ◽  
Christopher Lough ◽  
Matthew G. Zimmerman ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Effective Treatment ◽  
Treatment Option ◽  
Congenital Heart ◽  
Effective Treatment Option ◽  
Immune Systems ◽  
Key Points ◽  
Donor Variability

Key Points COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.

Sign in / Sign up

Export Citation Format

Share Document